Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma

Abstract

Summary:ently negative. [5][6][7] Furthermore, clonal Epstein-Barr viral infection has been documented in many of these cases. 6 Patients with primary nasal lymphoma usually present Primary nasal T or NK cell lymphoma is rarely seen in the Western population but is more common in the with local nasal symptoms and the tumour is often clinically localised. 3,8 However, the prognosis is generally poor Orientals. Although it often presents with localized disease, the prognosis is generally poor. Long-term as compared with their nodal counterparts. 8 Durable remission is only seen in around 50% of stage I patients remission is seen in only 50% of patients with stage I disease despite aggressive treatment with chemotherapy and the disease is invariably fatal if disseminated. For patients with relapsed disease, the prognosis is also dismal and radiotherapy, and is invariably fatal if disseminated. Conventional chemotherapy for relapsed disease as they almost all die with progressive disease within 1 year from the time of relapse. High-dose chemotherapy and is usually not successful. Since 1992, three patients with relapsed primary nasal T/NK cell lymphoma have autologous stem cell rescue has been shown to be an effective therapy for patients with relapsed aggressive nonreceived high-dose chemotherapy with autologous bone marrow rescue at Queen Mary Hospital, Hong Kong.Hodgkin's lymphoma. 9 We report our experience of using the approach to manage three patients with relapsed priHigh-dose cyclophosphamide, BCNU and etoposide were used for conditioning. Two of them had a favourmary nasal lymphoma. able response and remained in complete remission at 12 and 44 months post-transplant. The third patient unfortunately had a systemic relapse 6 months after the Case report transplant. It appears from this experience that, like other aggressive non-Hodgkin's lymphomas, high-dose Since 1992, three Chinese patients with relapsed primary nasal T/NK cell lymphoma have received high-dose chemochemotherapy and autologous bone marrow rescue is an effective treatment for relapsed primary nasal lymtherapy and autologous bone marrow rescue at the Bone Marrow Transplantation Unit of Queen Mary Hospital, phoma following failure of conventional chemotherapy and radiotherapy.Hong Kong. Their clinical characteristics are shown in Table 1. The conditioning regimen consisted of cyclophosKeywords: nasal lymphoma; autologous bone marrow transplantation phamide 1.8 g/m 2 /day for 4 days, BCNU 100 mg/m 2 /day for 3 days and etoposide 400 mg/m 2 12 h for six doses. The first patient was a 30-year-old woman. She presented with a nasal mass and symptoms of nasal obstruction in Primary nasal lymphoma is extremely uncommon in the February 1992. Biopsy of the tumour revealed a primary Western population. When it occurs, it often affects the nasal lymphoma (CD2 + , CD56 + ). Staging investigations nasal sinuses and is usually of B cell origin. On the other confirmed that she had disease localised to the nasal cavity. hand, it is much more common in the Orie...

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index

“…High-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) was offered to selected patients. 33 …”

High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases

“…7,8 Few reports have demonstrated promising results with highdose chemotherapy and autologous stem cell transplantation (HDC/ASCT) in NK/T-cell lymphoma patients as a salvage treatment. [9][10][11][12][13][14] It is inconclusive, however, from these studies, to consider HDC/ASCT as a standard treatment due to small cohort of patients. In addition, a clear indication of HDC/ASCT has not been established in NK/T-cell lymphomas.…”

Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL

“…Although, several studies have investigated the clinical efficacy of ASCT relative to historical controls in the settings of upfront or salvage therapy, the results have been inconclusive. 7,8,10,11,[18][19][20] Overall survival gain has been demonstrated for patients who were treated with ASCT compared to those who were treated with chemotherapy. 7,8 In particular, patients with high-risk NKPI and who attained CR demonstrated significantly improved survival after undergoing ASCT.…”